Bayforest Capital Ltd Invests $344,000 in Progyny, Inc. $PGNY

Key Points

• Bayforest Capital Ltd invested $344,000 in Progyny, Inc., acquiring 15,392 shares in the first quarter.
• Progyny's stock is currently valued at $22.63, reflecting a 1.5% decrease in value, with a market cap of $1.95 billion.
• After missing quarterly earnings expectations, Progyny has set guidance projecting EPS for FY 2025 between 1.700-1.780.

Bayforest Capital Ltd acquired a new position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 15,392 shares of the company's stock, valued at approximately $344,000.

A number of other large investors also recently modified their holdings of PGNY. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Progyny during the first quarter worth approximately $44,000. Brooklyn Investment Group increased its holdings in shares of Progyny by 5,216.4% during the first quarter. Brooklyn Investment Group now owns 3,243 shares of the company's stock worth $72,000 after purchasing an additional 3,182 shares during the period. GAMMA Investing LLC increased its holdings in shares of Progyny by 233.9% during the first quarter. GAMMA Investing LLC now owns 5,379 shares of the company's stock worth $120,000 after purchasing an additional 3,768 shares during the period. AlphaQuest LLC increased its holdings in shares of Progyny by 57.9% during the first quarter. AlphaQuest LLC now owns 5,668 shares of the company's stock worth $127,000 after purchasing an additional 2,079 shares during the period. Finally, Teza Capital Management LLC bought a new position in shares of Progyny during the first quarter worth approximately $213,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

PGNY has been the topic of a number of recent analyst reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $28.00 price objective (up from $26.00) on shares of Progyny in a research note on Friday, August 8th. JPMorgan Chase & Co. lifted their price target on shares of Progyny from $23.00 to $25.00 and gave the stock a "neutral" rating in a report on Tuesday, August 26th. Raymond James Financial set a $28.00 price target on shares of Progyny in a report on Friday, August 8th. Leerink Partners upgraded shares of Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 price target on the stock in a report on Tuesday, July 8th. Finally, Wall Street Zen upgraded shares of Progyny from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $25.30.

Progyny Trading Down 0.2%

Shares of NASDAQ:PGNY traded down $0.05 during trading on Tuesday, reaching $22.08. The company had a trading volume of 253,417 shares, compared to its average volume of 1,363,673. The stock has a market capitalization of $1.90 billion, a P/E ratio of 37.51, a price-to-earnings-growth ratio of 1.84 and a beta of 1.33. The company has a fifty day moving average of $23.07 and a two-hundred day moving average of $22.21. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $26.76.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.19 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.23). Progyny had a net margin of 4.28% and a return on equity of 10.69%. The firm had revenue of $332.87 million for the quarter, compared to analysts' expectations of $315.70 million. During the same period in the previous year, the company earned $0.17 EPS. The company's quarterly revenue was up 9.5% on a year-over-year basis. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. As a group, equities research analysts predict that Progyny, Inc. will post 0.6 earnings per share for the current year.

Insider Activity

In related news, Director Kevin K. Gordon sold 2,500 shares of Progyny stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $22.04, for a total transaction of $55,100.00. Following the completion of the transaction, the director directly owned 12,501 shares of the company's stock, valued at $275,522.04. This trade represents a 16.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Allison Swartz sold 2,398 shares of Progyny stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $22.96, for a total transaction of $55,058.08. Following the transaction, the executive vice president directly owned 79,697 shares of the company's stock, valued at approximately $1,829,843.12. This trade represents a 2.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,895 shares of company stock valued at $179,311. Corporate insiders own 9.40% of the company's stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.